Drug Profile
Cisplatin - NanoCarrier
Alternative Names: Cisplatin micellar nanoparticle; Micelplatin; Nanoplatin; NC-6004Latest Information Update: 28 Apr 2022
Price :
$50
*
At a glance
- Originator University of Tokyo
- Developer NanoCarrier; Orient Europharma
- Class Antineoplastics; Platinum complexes; Small molecules
- Mechanism of Action DNA cross linking agents; DNA synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase III Pancreatic cancer
- Phase II Biliary cancer; Bladder cancer; Head and neck cancer; Non-small cell lung cancer
Most Recent Events
- 28 Apr 2022 No recent reports of development identified for phase-I development in Head-and-neck-cancer(Combination therapy) in European Union (IV, Infusion)
- 28 Apr 2022 No recent reports of development identified for phase-I development in Head-and-neck-cancer(Combination therapy, First-line therapy, Metastatic disease, Recurrent) in Taiwan (IV, Infusion)
- 24 Oct 2020 Efficacy and adverse events data from a phase IIa/IIb trial in Head and neck cancer presented at 32nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR-2020)